Clinical Trials

A clinical trial is the final stage of a long and careful process required to bring new drugs or treatments to patients everywhere. These studies help find safe and effective approaches to disease prevention, diagnosis and treatment.

At some point in your treatment, a clinical trial may be a recommended next step. The advances that result from these studies help to improve the quality of cancer care for everyone.

Access to clinical trials

SCL Health monitors cancer clinical trials and offers qualified patients the opportunity to participate in those that fit their diagnostic, health and treatment history. By conducting clinical research within our cancer program, we provide patients with direct access to new and emerging science that may help to develop new ways to prevent, detect and treat cancer. Most of the cancer treatments used today are the result of past clinical trials, and many patients benefited by having early access to these lifesaving treatments.

Collaboration between cancer specialists

If you participate in a trial, a team of medical professionals, including oncologists, radiologists, pathologists, nurses, social workers, genetic counselors and research coordinators, work together to provide your care and manage the rules of the study.

Current Clinical Trials

Below you will find a number of clinical trials that are currently available at St. Vincent Healthcare Frontier Cancer Center. Please contact our Clinical Research Department for more information at 406-238-6685 or SVFCC-Research@sclhs.net.

Breast

Spectrum SPI-GCF-302

(NCT#02953340) – The purpose of this study is to compare the efficacy of SPI-2012 with pegfilgrastim in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) to prevent and reduce Neutropenia that is associated with cancer chemotherapy. Learn more about this clinical trial.

Merck MK-3475-355

(NCT#02819518) – The purpose of this study is to evaluate the efficacy and tolerability of poziotinib in patients with HER2-positive metastatic breast cancer who have received at least 2 prior HER2-directed treatment regimens. Learn more about this clinical trial.

Lung

BMS CA-209370
(NCT#02574078) – The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients. Learn more about this clinical trial.

BMS CA-209-816
(NCT#02998528) – The purpose of this study is to determine the safety and effectiveness of nivolumab and ipilimumab compared to chemotherapy in the treatment of Early Stage Non-Small Cell Lung Cancer. Learn more about this clinical trial.

Non-Hodgkin Lymphoma

TG Therapeutics UNITY DLBCL UTX-TGR-205
(NCT#02793583) – This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in combination with another study drug called ublituximab with or without bendamustine and TGR-1202 alone as a possible treatment for Non-Hodgkin's Lymphoma (NHL) that has come back or that has not responded to standard treatment. Learn more about this clinical trial.

Amgen AMG798NH-NHL798
(NCT#02747043) – This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with CD 20 positive B-cell non Hodgkin lymphoma. This study will assess if the investigational medicine is safe and effective in treating CD 20 positive B-cell non Hodgkin lymphoma. Learn more about this clinical trial.

Incyte INCB 39110-206
(NCT#02760485) – The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Learn more about this clinical trial.

Kidney

Pfizer B9991003
(NCT#02684006) - This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma. Learn more about this clinical trial.

Merck MK-3475-427
(NCT#02853344) – The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC). There will be two cohorts in this study: Cohort A will consist of participants with clear cell (cc) RCC and Cohort B will consist of participants with non-clear cell (ncc) RCC. Learn more about this clinical trial.

Merck MK-3475-564
(NCT#03142334) – The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma (RCC) with clear cell component. Learn more about this clinical trial.

Urothelial

Merck MK3475-361
(NCT#02853305) – The purpose of this study is to determine the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer). Learn more about this clinical trial.

AstraZeneca D4191C00068
(NCT#03084471) – To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors. Learn more about this clinical trial.

Prostate

Bayer BAY 1841788/17777
(NCT#02799602) - The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer. Learn more about this clinical trial.

Cholangiocarcinoma

Incyte INCB 54828-202
(NCT#02924376) – The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment. Learn more about this clinical trial.

Surveillance-Observational Studies

Celgene Connect® MDS/AML
(NCT#02856646) – The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses will also attempt to identify prognostic or predictive biomarkers. Learn more about this clinical trial.

BMS CA-209-655
(NCT#02856646) – The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses will also attempt to identify prognostic or predictive biomarkers. Learn more about this clinical trial.

Incyte INCB-MA-MF-401
(NCT#02953704) – The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF). Learn more about this clinical trial.

Pharmacyclics PCYC-1134M
(NCT#02582879) – The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens. This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL). Learn more about this clinical trial.

SCL Health is an equal opportunity employer. All recruiting, training, and employment decisions are made in accordance with applicable federal, state, and local laws and without regard to race, color, ancestry, national origin, gender, pregnancy, gender identity, sexual orientation, religion, age, disability, handicap, military or veteran status, or any other legally protected status.

NOTICE OF NONDISCRIMINATION

Our facilities do not discriminate against any person on the basis of race, color, national origin, disability, or age in admission or access to, or treatment or employment in, its programs, services or activities, or on the basis of sex (gender) in health programs and activities. Read the full notice: St. Vincent Healthcare Notice of Nondiscrimination